NEW YORK (GenomeWeb News) – Life Technologies today announced a commercialization deal covering three stem cell technologies from Cellular Dynamics International for the consistent development and growth of human iPS cells for research and bioproduction.

Life Tech will commercialize CDI's Essential 8 Medium, Vitronectin, and Episomal iPSC Reprogramming Vectors, which together address several challenges associated with developing relevant cells, the Carlsbad, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.